Ophthalmology Times1d
Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...
Medical Dialogues1d
Cipla gets exclusive rights to market ophthalmic drug across 11 countries
Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...
Cipla signs pact with Taiwan drug firm
Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...
Cipla enters into exclusive pact with Formosa to distribute ophthalmic drug
Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...
The Week3d
Cipla inks licensing agreement with Taiwan-based drug firm
Drug maker Cipla on Tuesday said it has inked an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension. As ...
The Financial Express3d
Cipla signs multi-regional licensing deal with Formosa for eye disorder
This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits, the company stated.
Adaderana Biz English3d
Cipla Partners with Formosa Pharma to Launch USFDA-Approved Eye Treatment in Sri Lanka and 10 Other Markets
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain ...
Le Lézard3d
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" for the commercialization of ...